Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
Ghana is advancing Phase 2 of its nuclear power programme, focusing on site studies, vendor negotiations, and public ...
Ian Mortimer, President and CEO, emphasized the nearing completion of patient recruitment for the X-TOLE2 Phase 3 epilepsy study and stated, "delivering data from our X-TOLE2 study remains our number ...
Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results